← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Lyndra Therapeutics, Inc.
Watertown, MA
$36,576,208
Total funding
8
Grants
Funding over time
peak $14.1M · FY2016–21$20M$15M$10M$5M$0
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$36,576,208 · 8
By mechanism
UG3$15,335,147 · 2
UH3$11,699,793 · 1
R01$6,516,268 · 1
R44$2,500,000 · 2
R43$525,000 · 2
Investigators at Lyndra Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A once-weekly oral methadone for maintenance therapy for opioid use disorder$11,699,793
UH3 · FY2021 · DA
A once-weekly oral methadone for maintenance therapy for opioid use disorder$6,854,394
UG3 · FY2019 · DA
An ultra-long-acting oral treatment for opioid use disorder$5,658,273
UG3 · FY2019 · DA
An ultra-long-acting oral treatment for opioid use disorder$2,543,976
UG3 · FY2018 · DA
Development of Ultra Long-Acting Oral HIV Therapies$1,323,542
R01 · FY2018 · AI
Development of Ultra Long-Acting Oral HIV Therapies$1,323,542
R01 · FY2017 · AI
Development of Ultra Long-Acting Oral HIV Therapies$1,323,542
R01 · FY2019 · AI
Development of Ultra Long-Acting Oral HIV Therapies$1,272,821
R01 · FY2020 · AI
Development of Ultra Long-Acting Oral HIV Therapies$1,272,821
R01 · FY2021 · AI
An Oral Ultra Long-Acting Ivermectin for Malaria Elimination$1,047,601
R44 · FY2017 · TR
A Once-Weekly Oral Tacrolimus-Prednisone Fixed-Dose Combination Therapy for Post-Transplant Maintenance Immunosuppressive Therapy$1,000,000
R44 · FY2020 · AI
An Oral Ultra Long-Acting Ivermectin for Malaria Elimination$452,399
R44 · FY2018 · TR
An Oral Long-Acting Doxycycline for Onchocerciasis Eradication: Process Improvement for Small Batch Manufacturing$300,000
R43 · FY2016 · AI
An ultra-long-acting oral treatment for opioid use disorder$278,504
UG3 · FY2019 · DA
Novel 3D Printed Architectures for Oral Long-acting Drug Delivery Systems$225,000
R43 · FY2017 · EB